PMID- 31302851
OWN - NLM
STAT- MEDLINE
DCOM- 20200317
LR  - 20200317
IS  - 1993-0402 (Electronic)
IS  - 1672-0415 (Linking)
VI  - 25
IP  - 9
DP  - 2019 Sep
TI  - Effect and Safety of Guanxinning Tablet () for Stable Angina Pectoris Patients 
      with Xin (Heart)-Blood Stagnation Syndrome: A Randomized, Multicenter, 
      Placebo-Controlled Trial.
PG  - 684-690
LID - 10.1007/s11655-019-3069-8 [doi]
AB  - OBJECTIVE: To investigate the effect and safety of Guanxinning Tablet (, GXN) for 
      the treatment of stable angina pectoris patients with Xin (Heart)-blood 
      stagnation syndrome (XBSS). METHODS: One hundred and sixty stable angina pectoris 
      patients with XBSS were randomly assigned to receive GXN (80 cases) or placebo 
      (80 cases, Guanxinning simulation tablets, mainly composed of lactose), 4 tablets 
      (0.38 g/tablet), thrice daily for 12 weeks. After treatment, an exercise stress 
      test (treadmill protocol), Chinese medicine (CM) syndrome score, 
      electrocardiogram (ECG), and nitroglycerin withdrawal rate were evaluated and 
      compared in the patients between the two groups. Meanwhile, adverse events (AEs) 
      were evaluated during the whole clinical trial. RESULTS: Compared with the 
      control group, the time extension of exercise duration in the GXN group increased 
      29.28 +/-17.67 s after treatment (P>0.05); moreover, the change of exercise 
      duration in the GXN group increased 63.10 +/-96.96 s in subgroup analysis (P<0.05). 
      The effective rates of angina pectoris, CM syndrome and ECG as well as 
      nitroglycerin withdrawal rate were 81.33%, 90.67%, 45.76%, and 70.73%, 
      respectively in the GXN group, which were all significantly higher than those in 
      the control group (40.58%, 75.36%, 26.92%, 28.21%, respectively, P<0.05). 
      CONCLUSION: GXN was a safe and effective treatment for stable angina pectoris 
      patients with XBSS at a dose of 4 tablets, thrice daily.
FAU - Sun, Ming-Yue
AU  - Sun MY
AD  - Good Clinical Practice Center, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Miao, Yang
AU  - Miao Y
AD  - Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Jin, Min
AU  - Jin M
AD  - Chiatai Qingchunbao Pharmaceutical Co., Ltd., Hangzhou, 310023, China.
FAU - Dong, Yao-Rong
AU  - Dong YR
AD  - Department of Cardiology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, 
      Shanghai, 200071, China.
FAU - Liu, Shu-Rong
AU  - Liu SR
AD  - Department of Cardiology, The First Clinical Hospital of Jilin Academy of Chinese 
      Medical Sciences, Changchun, 130021, China.
FAU - Wang, Mu-Lan
AU  - Wang ML
AD  - Chiatai Qingchunbao Pharmaceutical Co., Ltd., Hangzhou, 310023, China.
FAU - Gao, Rui
AU  - Gao R
AD  - Good Clinical Practice Center, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China. ruigao@126.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20190713
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Placebos)
RN  - 0 (Tablets)
SB  - IM
MH  - Angina, Stable/diagnostic imaging/*drug therapy
MH  - Drugs, Chinese Herbal/*adverse effects/*therapeutic use
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Syndrome
MH  - Tablets
OTO - NOTNLM
OT  - Chinese medicine
OT  - Guanxinning Tablet
OT  - Xin (Heart)-blood stagnation syndrome
OT  - coronary heart disease
OT  - stable angina pectoris
EDAT- 2019/07/16 06:00
MHDA- 2020/03/18 06:00
CRDT- 2019/07/15 06:00
PHST- 2017/05/05 00:00 [accepted]
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2020/03/18 06:00 [medline]
PHST- 2019/07/15 06:00 [entrez]
AID - 10.1007/s11655-019-3069-8 [pii]
AID - 10.1007/s11655-019-3069-8 [doi]
PST - ppublish
SO  - Chin J Integr Med. 2019 Sep;25(9):684-690. doi: 10.1007/s11655-019-3069-8. Epub 
      2019 Jul 13.